MedTrace Logo

Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas

NCT06217536 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2024-11-18

No results posted yet for this study

Summary

This is a multi-center, multi-arm open-label phase Ib/II clinical study assessing the efficacy of concurrent lurbinectedin in combination with radiotherapy in patients with locally advanced, resectable, high-grade sarcomas.

Conditions

  • Locally Advanced Soft Tissue Sarcoma

Interventions

DRUG

Lurbinectedin

Given intravenously (IV)

RADIATION

Radiotherapy

Conventionally fractionated radiotherapy or external beam radiation

PROCEDURE

Non-investigational surgery

Non-investigational surgical procedure on tumor tissue

Sponsors & Collaborators

Principal Investigators

  • Varun Monga, MD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-31
Primary Completion
2026-05-31
Completion
2027-10-31
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06217536 on ClinicalTrials.gov